{"name":"Travere Therapeutics, Inc.","slug":"travere","ticker":"TVTX","exchange":"NASDAQ","domain":"travere.com","description":"Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with Ph","hq":"San Diego, CA","founded":2013,"employees":"497","ceo":"Eric Dube","sector":"Rare Disease","stockPrice":43.91,"stockChange":-0.64,"stockChangePercent":-1.44,"marketCap":"$4.1B","metrics":{"revenue":536195008,"revenueGrowth":55.6,"grossMargin":55.9,"rdSpend":7500000,"netIncome":-25546000,"cash":93035000,"dividendYield":0,"peRatio":8.8,"fiscalYear":"FY2012"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Prograf patent cliff ($143.8M at risk)","drug":"Prograf","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Travere Therapeutics reported its fourth quarter and full year 2023 financial results, with revenue of $143.8 million and a net loss of $44.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Travere Therapeutics Announces Collaboration with the National Kidney Foundation","summary":"Travere Therapeutics announced a collaboration with the National Kidney Foundation to support patients with rare kidney diseases.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Travere Therapeutics' Prograf for Kidney Transplant Patients","summary":"The FDA approved Prograf for the prevention of organ rejection in kidney transplant patients.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOUk1Ya3Q4clRIOUVYRGF3eTlhaXNyUm9weDNkOXQ5ejNVYWRJMUNZemNmZHozanFjMFpCOVNpZlBvVG9GMXFDemVXYXhSWm92UUZhMjlvZjZlUmFnMHozd1drSDFSQTNPUG9GV0MtVEc0c2tIOEpzd3gxTGxzQUR3Tjc1SHB4N3kwWXQzYXJlaXpPQzR4X3VMV0NRd05lQQ?oc=5","date":"2026-03-10","type":"pipeline","source":"Finviz","summary":"Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) - Finviz","headline":"Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPdzZjSm56T3RwMHN3aUhWNktqY3dtZ3YtNDY1YzE3NnlWQ2hQRnQ4bG45bzJsWkhueG5sRmhFTENBQVZTckVkM1JZU3lTTVpnVXdnbGpWT1Qtck5iYTlKYzFtTnNFYXN5M2pxZmkydGZBM0hsMHp5SXZaaHFfZXBTY0FPemZBMVJqQzVqT1pmOHJEaFdNVjloSzQ5d0ljMjd1MnpQNg?oc=5","date":"2026-02-19","type":"pipeline","source":"TradingView","summary":"Travere Therapeutics, Inc. SEC 10-K Report - TradingView","headline":"Travere Therapeutics, Inc. SEC 10-K Report","sentiment":"neutral"},{"date":"2026-02-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNaXllVGloSThjUm4xYk5QalY3LUNpYjlTSFpfREFyelI3T0R0LXRfb1pyOE12ZUVuZHFZdTI2RHo4eWt5NENqRGl1QU1NLThoZUFJNGl6VDVTZllaVmhOZmFla2c3SU1DUS1oOHE3NEtaak9RMW1jVmo4S2hzQTZLam5tUldiMHdEVUpVYlFfdWc5azZZZGMzbWljT3NzMnp6aVZFWWFCZy1TS0tDZUVmSGFqYlViWEcxSTU5R0dseDZZVjIyWU1xSF9xOEtmbktmVzZWRzRuVGJaVmxrN1JkZnBUcXZkSnFDN0JQdFNXVEhuLUFkd3loZk54cW4xSE9pdmpTTlRhTUpIR3VsNDhvQU9B?oc=5","date":"2026-01-23","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNb3AzTzU3ZS1KSVkydmt3YjZSbVpfS3FfcU5UZ09sSURtZndIM01RVW84cUpmX2xwdU45bWhjZFB2bVNEdGZJVllQTjVTQTJ3NlEyUW85UmRkaHVMYktVQWgtUTE0QTZLT1NKeGZoX1ZwRFl4cHlwM215U2lJMVBLb29wNlpoOUdqdjJkd05yWGNpcVRjcjRfdDM3STFBN21Da2lXeTU0WQ?oc=5","date":"2026-01-13","type":"pipeline","source":"Investor's Business Daily","summary":"Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug - Investor's Business Daily","headline":"Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOMXo0THVHWmlpZGx1Q09IczlSMGJSWi16bDRGd2RaSzVOVWd6Q1pYM3pUYjgzT0ZITVNtdkFmbXZvcWRLNFNvcmk3VzlJZERVdDZqcXBqaUlHU3JiekQxYjY1OWhLRTFReFNiUWJUdnNuM3BzQ2ExYUV5MkVUMDN3Z1YwaXZIOXVZdkQtY19zUkhmWjVBaXBYT2RmQkczd1NqSDZ0OUJn?oc=5","date":"2026-01-13","type":"pipeline","source":"BioSpace","summary":"Travere Therapeutics Provides Corporate Update and 2026 Outlook - BioSpace","headline":"Travere Therapeutics Provides Corporate Update and 2026 Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOMG9Mb1hmb1ozcTNxcHp5VkZoY083VVAzbDFVRzRKVHVYcUp1b1dfRURjV09heXJzV3pqdGN3c1BfTjBJb29BZU9xYWxWU1A1MlR0NHJnendxZFFSVzdMSllxNEp1d3VfdWhXM2M4bHVwaHRXM2J6bUhud3dySF8taldCOXV5WmJoZkNKUmd5MGZUYnZqNzJXSGFoNmZvUkdsS2ZfZXdzWnZNN2dKRERsYUVRWHc0Z1lJWERSdWhxdGFqLWxoT3c?oc=5","date":"2026-01-13","type":"regulatory","source":"Reuters","summary":"Travere shares fall as US FDA extends review of rare kidney disease drug - Reuters","headline":"Travere shares fall as US FDA extends review of rare kidney disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOTkl4SXNDSG9PUnFPdzUzVFVOTTlpWlhiM1Y0ZkhGbEYwSGNkb0NERldLRzJLMGRzdzNnMUYwZTk0WFBSaEdRWktFcGo0UjB1MUlDRFBldWNtdFVGWGlzUEQ1V280SUdRR1RjQ0NWOC1udmM4ckNnaGxIX3NOVjFZOFNRQmVXMVJPNjFnbDdtbGt4eGJud1o0bUowMA?oc=5","date":"2026-01-06","type":"regulatory","source":"TechStock²","summary":"Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears - TechStock²","headline":"Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPbU5uS0ZhczloYmdnLXFhZFZpaGZCX0lFd3o2aThwZVpLZC1YNjJjb29yR3NfQ19udzdzZElXVFdfR3h5YmpEMC1vVFFBVU9PMmZkOEFYalFvUmhfR3JISGs1eGhFcFpmTDBpakdyVXFhcmVKcXhOOGd5dHQwa1RBd0ctdGRuclliOW9URjRoRmJ4bndrbzNyWUs1VG1GUklpN0hLZWJuRTBrWmd1ZmxjNlJralhyNjg?oc=5","date":"2025-11-26","type":"pipeline","source":"Seeking Alpha","summary":"Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA (TVTX) - Seeking Alpha","headline":"Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA (TVTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE12cndFaXlYVE9NNDBXSnZGZkc1azNmUU80c1VXS1dtdzV1QVFPQmh0SFNaRm92MUQyOGFQY3JBTklkRGRkQjMxQkM1TUVqMGJYMUNVQkZ4NjNvWDFMT1JtcGV4d3pYRVhMRzcxUnVxLU5rTDNDOVE?oc=5","date":"2025-07-20","type":"pipeline","source":"TradingView","summary":"TVTX Options Volatility — NASDAQ:TVTX - TradingView","headline":"TVTX Options Volatility — NASDAQ:TVTX","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-29","type":"pipeline","source":"simplywall.st","summary":"Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt? - simplywall.st","headline":"Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5TZl9TcFBxNEVrZjM4ZW9HN1Jtc3pDeF9WZ1ZiS1hnSGRDWUg4SnlkdmFLenA2NkRVTVFMS0tRR29CV2lyUXNPcU51OXg0MXRPZk9v?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"TVTX Stock Price, News & Analysis - Stock Titan","headline":"TVTX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE50ZkoxOUVId0c3RW1fU092RVZGSUp1M1h4amZkVVlBT3BMOEp5bExPSDdrS3VBUnJiM254VnhtdGtabHJpcFNiYUdsdWhhaE5iQ2c?oc=5","date":"2021-01-30","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Prograf","drugSlug":"tacrolimus","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":143800000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["AstraZeneca","Pfizer","Sanofi"],"therapeuticFocus":["Nephrology","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2012-02-29","revenueHistory":[{"value":0,"period":"2012-02-29"},{"value":0,"period":"2011-02-28"}],"grossProfit":480389000,"grossProfitHistory":[{"period":"2025-12-31","value":480389000},{"period":"2024-12-31","value":225431000},{"period":"2023-12-31","value":133788000},{"period":"2022-12-31","value":105040000}],"rdSpend":7500000,"rdSpendHistory":[{"period":"2025-12-31","value":206011000},{"period":"2024-12-31","value":282701000},{"period":"2023-12-31","value":244990000},{"period":"2022-12-31","value":227333000}],"sgaSpend":337202000,"operatingIncome":-62824000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-62824000},{"period":"2024-12-31","value":-321389000},{"period":"2023-12-31","value":-376744000},{"period":"2022-12-31","value":-319813000}],"netIncome":-25546000,"netIncomeHistory":[{"period":"2025-12-31","value":-25546000},{"period":"2024-12-31","value":-321545000},{"period":"2023-12-31","value":-111399000},{"period":"2022-12-31","value":-278482000}],"eps":-0.29,"epsHistory":[{"period":"2025-12-31","value":-0.29},{"period":"2024-12-31","value":-4.08},{"period":"2023-12-31","value":-1.5},{"period":"2022-12-31","value":-4.37}],"cash":93035000,"cashHistory":[{"period":"2025-12-31","value":93035000},{"period":"2024-12-31","value":58535000},{"period":"2023-12-31","value":58176000},{"period":"2022-12-31","value":61688000}],"totalAssets":605191000,"totalLiabilities":490363000,"totalDebt":328733000,"equity":114828000,"operatingCashflow":37784000,"operatingCashflowHistory":[{"period":"2025-12-31","value":37784000},{"period":"2024-12-31","value":-237475000},{"period":"2023-12-31","value":-280021000},{"period":"2022-12-31","value":-186291000}],"capex":-58157000,"capexHistory":[{"period":"2025-12-31","value":-58157000},{"period":"2024-12-31","value":-101212000},{"period":"2023-12-31","value":-41591000},{"period":"2022-12-31","value":-28366000}],"freeCashflow":-20373000,"dividendsPaid":null,"buybacks":null,"employees":497,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":80254000,"ebit":-34422000,"ebitda":-9210000,"period":"2026-03-31","revenue":127199000,"epsBasic":-0.4,"netIncome":-37102000,"rdExpense":57094000,"epsDiluted":-0.4,"grossProfit":100433000,"operatingIncome":-36915000},{"sga":101694000,"ebit":-18769000,"ebitda":-632000,"period":"2025-12-31","revenue":129689000,"epsBasic":0.03,"netIncome":2729000,"rdExpense":57870000,"epsDiluted":0.03,"grossProfit":127136000,"operatingIncome":-32428000},{"sga":86453000,"ebit":28465000,"ebitda":44253000,"period":"2025-09-30","revenue":164859000,"epsBasic":0.29,"netIncome":25706000,"rdExpense":51890000,"epsDiluted":0.28,"grossProfit":163274000,"operatingIncome":24931000},{"sga":76216000,"ebit":-9889000,"ebitda":4127000,"period":"2025-06-30","revenue":114449000,"epsBasic":-0.14,"netIncome":-12755000,"rdExpense":49362000,"epsDiluted":-0.14,"grossProfit":112928000,"operatingIncome":-12650000},{"sga":60413000,"ebit":-38330000,"ebitda":-25528000,"period":"2025-03-31","revenue":81732000,"epsBasic":-0.47,"netIncome":-41226000,"rdExpense":46889000,"epsDiluted":-0.47,"grossProfit":64628000,"operatingIncome":-42674000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":43.91,"previousClose":44.55,"fiftyTwoWeekHigh":48.61,"fiftyTwoWeekLow":13.88,"fiftyTwoWeekRange":"13.88 - 48.61","fiftyDayAverage":34.54,"twoHundredDayAverage":29.89,"beta":1.14,"enterpriseValue":4205819904,"forwardPE":8.8,"priceToBook":34.77,"priceToSales":7.62,"enterpriseToRevenue":7.84,"enterpriseToEbitda":261.43,"pegRatio":0,"ebitda":16088000,"ebitdaMargin":3,"freeCashflow":-51166000,"operatingCashflow":39612000,"totalDebt":327662016,"debtToEquity":331.9,"currentRatio":3.13,"returnOnAssets":-6.5,"returnOnEquity":-69.4,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":53.57,"targetHighPrice":60,"targetLowPrice":43,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.8,"institutionHeldPercent":114,"sharesOutstanding":92992905,"floatShares":91984862,"sharesShort":14216705,"shortRatio":5.44,"shortPercentOfFloat":15.3,"epsTrailing":-0.5,"epsForward":5.01,"revenuePerShare":5.95,"bookValue":1.26,"officers":[{"age":52,"name":"Dr. Eric M. Dube Ph.D.","title":"President, CEO & Director"},{"age":40,"name":"Mr. Christopher  Cline C.F.A.","title":"Chief Financial Officer"},{"age":62,"name":"Dr. William E. Rote Ph.D.","title":"Chief Research Officer"},{"age":54,"name":"Mr. Peter  Heerma","title":"Chief Commercial Officer"},{"age":50,"name":"Dr. Jula  Inrig M.D.","title":"Chief Medical Officer"},{"age":59,"name":"Ms. Sandra  Calvin","title":"SVP, Corporate Controller & Chief Accounting Officer"},{"age":null,"name":"Ms. Nivi  Nehra","title":"Vice President of Corporate Communications & Investor Relations"},{"age":54,"name":"Ms. Elizabeth E. Reed J.D.","title":"Chief Legal Officer, General Counsel & Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://travere.com","phone":"888 969 7879"}}